GlassScriptPhysician profile
Taryn Tootle
NPI 1144956426
$3,291.45
in general payments reported to CMS, 2019-2025
33 companies · $535 in 2025
The $535 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $220 · 2023: $1,397 · 2024: $1,139 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.62 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $542.94 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $437.92 | 2023-2025 | |
| Corium, LLC | $332.92 | 2022-2024 | Azstarys, Azstarys |
| Glaxosmithkline, LLC. | $249.68 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $202.20 | 2023-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $197.80 | 2023-2025 | |
| Novo Nordisk INC | $179.56 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Antares Pharma, INC. | $118.92 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $118.02 | 2023-2025 | Repatha, Otezla, Repatha |
| Idorsia Pharmaceuticals US INC | $84.80 | 2023-2025 | Quviviq, Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.30 | 2023-2024 | Jardiance |
| Dexcom, INC. | $80.43 | 2022-2025 | Dexcom G6 Transmitter, Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Exact Sciences Corporation | $73.38 | 2023-2024 | Cologuard Collection Kit |
| Medtronic, INC. | $66.58 | 2024 | Venaseal |
| Merck Sharp & Dohme LLC | $60.35 | 2022-2023 | Verquvo, Dificid, Steglatro |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $57.51 | 2023-2024 | Breztri, Farxiga, Evusheld |
| Biohaven Pharmaceutical Holding Company LTD. | $54.02 | 2022 | |
| Abbott Laboratories | $48.07 | 2024 | Freestyle Libre 3 |
| Halozyme INC | $34.48 | 2023 | |
| Janssen Pharmaceuticals, INC | $32.51 | 2023 | Xarelto |
| Noven Therapeutics, LLC | $27.75 | 2023 | Xelstrym |
| Tris Pharma INC | $23.86 | 2023 | Dyanavel Xr, Quillichew Er, Quillivant |
| Philips North America LLC | $22.92 | 2024 | (Ck7) Extended Holter |
| Otsuka America Pharmaceutical, INC. | $22.13 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.22 | 2025 | Caplyta |
| Nevro Corp. | $18.08 | 2023 | Senza |
| Azurity Pharmaceuticals, INC. | $16.58 | 2025 | Alvesco |
| Takeda Pharmaceuticals U.S.A., INC. | $15.77 | 2023 | Trintellix |
| Ibsa Pharma INC. | $15.69 | 2023 | Tirosint, Licart |
| Novartis Pharmaceuticals Corporation | $13.66 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.58 | 2024 | Xifaxan |
| Organon LLC | $12.74 | 2024 | |
| Bausch Health US, LLC | $12.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taryn Tootle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.